- Home
- CRNX
as 10-17-2025 3:58pm EST
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.8B | IPO Year: | 2018 |
| Target Price: | $74.45 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.10 - $62.53 | Next Earning Date: | 11-06-2025 |
| Revenue: | $1,392,000 | Revenue Growth: | 0.51% |
| Revenue Growth (this year): | 428.87% | Revenue Growth (next year): | 958.11% |
Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Oct 1 '25 | Sell | $41.81 | 5,000 | $209,050.00 | 66,270 | |
| Struthers Richard Scott | CRNX | President & CEO | Sep 26 '25 | Sell | $45.00 | 4,000 | $180,000.00 | 106,000 | |
| Fust Matthew K | CRNX | Director | Sep 26 '25 | Sell | $44.75 | 16,000 | $716,000.00 | 22,836 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Sep 2 '25 | Sell | $32.10 | 5,000 | $160,500.00 | 66,270 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Aug 22 '25 | Sell | $30.43 | 30,000 | $912,900.00 | 66,270 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Aug 20 '25 | Sell | $29.18 | 6,492 | $189,436.56 | 66,270 |
Latest Crinetics Pharmaceuticals Inc. News
CRNX Breaking Stock News: Dive into CRNX Ticker-Specific Updates for Smart Investing
MT Newswires
17 days ago
Crinetics Pharmaceuticals Insider Sold Shares Worth $716,000, According to a Recent SEC Filing
Insider Monkey
18 days ago
JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval
Insider Monkey
18 days ago
JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating
Insider Monkey
18 days ago
Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug
GlobeNewswire
a month ago
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Clinical Trials Arena
a month ago
CTSWC25: The future of clinical trial supply hinges on risk management
MT Newswires
4 months ago
Crinetics Pharmaceuticals Insider Sold Shares Worth $3,141,877, According to a Recent SEC Filing
GlobeNewswire
4 months ago
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
Compare CRNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRNX Crinetics Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.